Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 30, 2026
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
08:00am, Friday, 02'nd Aug 2024
DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibio
Iterum Therapeutics Commences Rights Offering
07:30am, Monday, 22'nd Jul 2024
DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024 Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024
Iterum Therapeutics Reports First Quarter 2024 Financial Results
07:00am, Monday, 13'th May 2024
- -NDA Resubmitted; FDA Action Expected in Early Q4 24-- - -Cash Runway into 2025, including through Potential FDA Approval--
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
08:00am, Monday, 06'th May 2024
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
08:00am, Monday, 29'th Apr 2024
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024--
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript
10:08am, Thursday, 28'th Mar 2024
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
07:00am, Thursday, 28'th Mar 2024
- -Resubmission of NDA On Track for Early Q2 24— - -Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ire
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
04:30pm, Thursday, 21'st Mar 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
08:00am, Friday, 15'th Mar 2024
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral anti
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
09:00am, Thursday, 07'th Mar 2024
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority to Augmentin ® ; Demonstrated Statistical Superiority Re-submission of NDA to FDA Expected in Q2 2024 Potential to be First Oral Penem A
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
08:00am, Monday, 04'th Dec 2023
DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
07:00am, Tuesday, 14'th Nov 2023
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024- - DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Th
